É um tipo de câncer que se desenvolve nas células de revestimento da pleura (a membrana que envolve os pulmões) ou do peritônio (a membrana que reveste o abdômen e seus órgãos). Ele está associado à exposição ao amianto.
Introdução
O que você precisa saber de cara
O **mesotelioma** é um câncer raro que afeta o tecido de revestimento dos pulmões (pleura) ou da cavidade abdominal (peritônio), tendo como principal fator de risco a exposição ao amianto. A pessoa pode notar falta de ar, dores persistentes no peito ou na barriga, tosse e perda de peso sem explicação evidente. No Brasil, existe uma diretriz oficial voltada ao diagnóstico da doença na pleura, mas o protocolo do SUS não preconiza o fornecimento de medicamentos específicos para dispensação na farmácia pública. Existem pesquisas clínicas ativas com locais de recrutamento no Brasil avaliando novas abordagens terapêuticas para o cuidado dos pacientes.
É um tipo de câncer que se desenvolve nas células de revestimento da pleura (a membrana que envolve os pulmões) ou do peritônio (a membrana que reveste o abdômen e seus órgãos). Ele está associado à exposição ao amianto.
Tem tratamento?
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 15 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 28 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
3 genes identificados com associação a esta condição. Padrão de herança: Not applicable.
Frasier syndrome
Characterized by a slowly progressing nephropathy leading to renal failure in adolescence or early adulthood, male pseudohermaphroditism, and no Wilms tumor. As for histological findings of the kidneys, focal glomerular sclerosis is often observed. There is phenotypic overlap with Denys-Drash syndrome. Inheritance is autosomal dominant.
Medicamentos aprovados (FDA)
2 medicamentos encontrados nos registros da FDA americana.
Variantes genéticas (ClinVar)
4.451 variantes patogênicas registradas no ClinVar.
Vias biológicas (Reactome)
10 vias biológicas associadas aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Mesotelioma
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
Com ensaio aberto em 30 países. O ponto verde marca onde há vaga agora.
🟢 Recrutando agora
63 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
504 ensaios clínicos encontrados, 104 ativos.
Publicações mais relevantes
Mostrando amostra de 200 publicações de um total de 3.397
TGF-β Inhibition Through Combinatory Strategies Suppresses Proliferation and Invasiveness in Malignant Pleural Mesothelioma.
Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor associated with asbestos exposure, which represents a current problem. MPM is characterized by a poor prognosis and an unsatisfactory therapeutic approach. Therefore, improving MPM prognosis is the real challenge for research today. Regarding preclinical data, Transforming Growth Factor-β (TGF-β) plays a crucial role in cancer, and its alteration has been associated with tumor progression and invasiveness, in particular through the Epithelial to Mesenchymal Transition (EMT) event. We investigated the role of TGF-β inhibition in proliferation, cell cycle, migration, and invasiveness in human MPM cells. Data obtained clearly highlighted how TGF-β inhibition, through the silencing or treatment of MPM cells with antibody anti-TGF-β (Fresolimumab), significantly reduces cell proliferation (MTT, PCNA) and prevents metastasis, reducing EMT and decreasing the invasiveness and migration of MPM cells. Finally, we also evaluated TGF-β inhibitory effects in 3D MPM cellular models (spheroids), highlighting a significant slowdown in the growth rate of spheroids treated with anti-TGF-β antibody or Fresolimumab, confirming the results previously obtained. Taken as a whole, targeting TGF-β will represent a starting point for future improvements in MPM management. This is particularly important as we foresee a growing increase in MPM in the coming years.
Targeting fatty acid synthase suppresses tumor development in NF2/CDKN2A-deficient pleural mesothelioma.
Pleural mesothelioma (PM) is an uncommon yet deadly cancer linked to asbestos exposure. The lack of effective early diagnosis and treatment leads to reduced life expectancy among patients with PM. This study aims to identify a novel molecular target inhibitor to develop more effective therapeutics for PM. Our drug screening assay showed that the fatty acid synthase (FASN) inhibitor cerulenin demonstrates strong and selective antiproliferative properties against NF2/CDKN2A(p16)-deficient PM cells, surpassing the effects of C75, cisplatin or pemetrexed. FASN protein is frequently detected in NF2/p16-deficient PM tumor-derived tissues (15/15, 100%), but rarely in NF2/p16-intact PM tumors (8/25, 32%). Notably, cerulenin administration successfully reduced the growth of NF2/p16-deficient PM tumors in xenografted mice. Cerulenin inhibits mitochondrial fission by targeting dynamin-related protein 1 (DRP1) in NF2/p16-deficient cells. Moreover, the disruption of the FASN gene leads to increased ubiquitination of DRP1. These findings suggest that FASN might play a role in the tumorigenesis of PM cells through the regulation of mitochondrial dynamics. This research offers a novel perspective on the potential development of precision medicine for PM.
Medical thoracoscopy with talc poudrage and indwelling pleural catheter insertion versus medical thoracoscopy with talc poudrage alone for patients with symptomatic malignant pleural effusion (TACTIC): a randomised, controlled phase 3 trial.
Patients with suspected malignant pleural effusions (MPE) are often in need of both a confirmatory diagnosis and symptom control. Therapeutic options include talc pleurodesis via chest drain, poudrage during medical thoracoscopy, or alternatively an indwelling pleural catheter (IPC). Combining the diagnostic and therapeutic efficacy of medical thoracoscopy and poudrage with the ambulatory benefits of an IPC has not been studied within a randomised controlled trial. The aim of the TACTIC trial was to determine whether this approach resulted in a reduced length of hospital stay and improvements in dyspnoea. This unblinded, phase 3, randomised controlled trial was undertaken in 11 UK hospitals. Patients with MPE and confirmed malignancy (during medical thoracoscopy or beforehand) received talc poudrage and were randomly assigned by a centralised web-based system to an IPC at the time of medical thoracoscopy or usual care (ie, medical thoracoscopy, poudrage, and admission with large bore tube). Co-primary outcomes were time in hospital (including initial admission for trial procedure and any subsequent readmissions over 4 weeks post procedure) and average breathlessness assessed with visual analogue scale dyspnoea scores, measuring severity of dyspnoea from 0 mm to 100 mm, over a 4-week period. All randomised patients in whom an outcome was available were included in the analysis on a modified intention-to-treat basis. TACTIC was registered with ISRCTN on Aug 8, 2021 (ISRCTN11058680). Participants were recruited from between Dec 15, 2021, and Jan 3, 2024. 124 participants were randomised: 62 to the intervention and 62 to standard care. Leading diagnoses were pleural mesothelioma (46%), lung cancer (28%), and breast cancer (10%). Co-primary outcome data were available for 102 patients for total length of hospital stay (52 in intervention group vs 50 in standard care group) and 108 patients for breathlessness (57 vs 51). Median time in hospital was 1 day (IQR 1-3, 95% CI 1-2) in the intervention group versus 2 days (IQR 1-3, 95% CI 1-2) in standard care group (p=0·26). Median visual analogue scale dyspnoea scores did not differ between groups: 14·0 mm (IQR 8·8-32·4) in the intervention group versus 19·6 mm (8·1-38·7) in standard care group (p=0·26). Participants in the intervention group required fewer additional invasive pleural procedures by 12 weeks (two [3%] of 60 vs 19 [34%] of 56, p<0·0001) Trial related adverse events rates were similar in both groups (46 [74%] of 62 vs 44 [71%] of 62, p=0·84). Three related serious adverse events were recorded, all occurring in the intervention group. The combination of medical thoracoscopy, poudrage, and IPC did not result in shorter hospital stay but was safe and resulted in similar dyspnoea control compared with standard care. For patients with symptomatic MPE undergoing medical thoracoscopy for pleurodesis who prioritise minimising the length of hospital stay or the need for further invasive pleural procedures, the addition of an IPC alongside poudrage might help to achieve this goal. National Institute of Health Research, Research for Patient Benefit.
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.
In this 5-year follow-up from the CheckMate 743 study in patients with unresectable pleural mesothelioma (PM), we evaluated updated efficacy and safety outcomes and biomarkers and performed treatment-switching analyses with first-line nivolumab plus ipilimumab versus chemotherapy. With a median follow-up of 66.8 months, nivolumab plus ipilimumab demonstrated continued overall survival (OS) benefit versus chemotherapy in all randomly assigned patients (5-year OS rates, 14% v 6%; hazard ratio [HR], 0.74 [95% CI, 0.62 to 0.88]); similar benefit was observed regardless of tumor histology. Of biomarker-evaluable patients treated with nivolumab plus ipilimumab (n = 242), high baseline monocytic myeloid-derived suppressor cell (M-MDSC) levels correlated with worse OS versus low M-MDSC levels (HR, 1.25 [95% CI, 1.09 to 1.43]). After adjusting for 24% of patients in the chemotherapy arm who received subsequent immunotherapy, nivolumab plus ipilimumab demonstrated continued OS benefit versus chemotherapy (HR, 0.64 [95% CI, 0.53 to 0.78]). No new safety signals were observed. These results demonstrate long-term, durable clinical benefit with nivolumab plus ipilimumab versus chemotherapy, which continued to be preserved even after treatment-switching adjustment in the chemotherapy arm. Exploratory analyses suggested greater benefit with nivolumab plus ipilimumab in the low M-MDSC subgroup. These results further support first-line nivolumab plus ipilimumab as standard of care for unresectable PM.
SATB2 Induces Malignant Transformation and Cancer Stem Cell Characteristics, and Inhibition of Its Expression Reverses Drug Resistance in Mesothelioma.
SATB2 (special AT-rich binding protein 2) functions as a chromatin-associated epigenetic regulator that modulates gene expression, in part by serving as a transcriptional cofactor. This study assessed whether SATB2 overexpression is sufficient to promote in vitro transformation of human mesothelial cells and whether SATB2 suppression in mesothelioma cancer stem cell (CSC)-enriched populations is associated with altered chemoresistance. SATB2 expression was high in human malignant pleural mesothelioma (MPM) cell lines but absent in Met5A mesothelial cells. Ectopic SATB2 expression in Met5A cells was associated with acquisition of malignant and stem cell-like phenotypes, including increased expression of stem cell markers and pluripotency-associated factors, as well as anchorage-independent growth in soft agar and spheroid formation in suspension culture. In contrast, Met5A cells transduced with an empty vector did not form colonies or mesospheres. SATB2 overexpression in Met5A cells was also associated with increased motility, migration, and invasion, accompanied by induction of epithelial-mesenchymal transition (EMT)-related transcription factors relative to empty vector controls. Conversely, shRNA-mediated SATB2 knockdown in an MPM cell line attenuated proliferation, EMT-associated features, and CSC-like characteristics. Chromatin immunoprecipitation assays identified SATB2 occupancy at promoter regions of Bcl2, XIAP, KLF4, c-Myc, NANOG, and SOX2, consistent with a role in transcriptional regulation of genes linked to transformation, pluripotency, cell survival, proliferation, and EMT. In CSC-enriched cells, SATB2 inhibition was associated with increased sensitivity to cisplatin and pemetrexed, concomitant with reduced OCT4 and SOX2 expression. Collectively, these findings support SATB2 as a candidate therapeutic target in MPM and suggest that SATB2 suppression may enhance chemotherapy response when combined with standard agents.
Publicações recentes
Regional immunosuppression and associated systemic markers in focally relapsed sarcomatoid mesothelioma: case report.
MET amplification in diffuse pleural mesothelioma and response to savolitinib: a case report.
Update on pleural mesothelioma.
From biology to therapy: current standards and emerging strategies in pleural mesothelioma.
Gene Expression and Immunohistochemical Phenotypes of High-Grade Epithelioid Mesothelioma.
📚 EuropePMC4.799 artigos no totalmostrando 194
Case Report: Immune checkpoint inhibitor-triggered anti-Ma2 paraneoplastic encephalitis in sarcomatoid pleural mesothelioma: a fatal case.
Frontiers in oncologySpain's Pleural Cancer Mortality 1984-2023: Insights From a Delayed Asbestos Prohibition.
Archivos de bronconeumologiaGenomic landscape of pleural mesothelioma in Japanese patients: A comprehensive analysis using nationwide database.
Translational oncologyMalignant mesothelioma of the tunica vaginalis testis: A case report.
Oncology lettersPersistence burden and poor survival of pleural mesothelioma in central Italy, 2013-2022: a population-based study thirty years after asbestos ban.
BMC public healthDiffuse Pleural Mesothelioma in Young (Age ≤50 Years) and Very Young (Age ≤35 Years) Patients: Clinical Characteristics, Genomics, and Survival.
JCO precision oncologyCytoreductive Surgery With or Without HITHOC for Pleural Mesothelioma: A Meta-analysis of Survival and Perioperative Outcomes.
Annals of surgical oncologyFactors affecting prognosis in patients diagnosed with epithelioid pleural mesothelioma who underwent surgery.
Turk gogus kalp damar cerrahisi dergisiThe International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Impact of Common Molecular Alterations and PD-L1 Expression on Overall Survival in a Select Cohort from the IASLC 9th Edition Staging Database.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung CancerTGF-β Inhibition Through Combinatory Strategies Suppresses Proliferation and Invasiveness in Malignant Pleural Mesothelioma.
International journal of molecular sciencesMulti-omics integration reveals tumor and microenvironmental heterogeneity in malignant pleural mesothelioma.
Discover oncologyCorrigendum to "Negative modulation of mitochondrial oxidative phosphorylation by epigallocatechin-3 gallate leads to growth arrest and apoptosis in human malignant pleural mesothelioma cells" [Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 1832(12) (2013) 2085-2096].
Biochimica et biophysica acta. Molecular basis of diseasePleural mesothelioma with net-like structures.
Internal medicine (Tokyo, Japan)Convex-probe endobronchial ultrasound-guided cryobiopsy for pleural tumors: three case reports.
Translational lung cancer researchRecovery from fulminant immune-related myocarditis induced by ipilimumab plus nivolumab in malignant pleural mesothelioma: a case report.
BMC pulmonary medicineMalignant Pleural Mesothelioma (MPM) Evaluation with [11C]-Methionine PET/CT Before and After Talc Pleurodesis.
Molecular imaging and biologyAdvancing Rare Cancer Therapeutics: Osimertinib-Loaded Inhaled PLGA Nanoparticles for Mesothelioma Treatment.
AAPS PharmSciTechEffects of Autophagy Inhibition by SAR405, a Selective VPS34 Inhibitor, on Pleural Mesothelioma Cells.
Thoracic cancerTargeting fatty acid synthase suppresses tumor development in NF2/CDKN2A-deficient pleural mesothelioma.
Cell death & diseaseMedical thoracoscopy with talc poudrage and indwelling pleural catheter insertion versus medical thoracoscopy with talc poudrage alone for patients with symptomatic malignant pleural effusion (TACTIC): a randomised, controlled phase 3 trial.
The Lancet. Respiratory medicineEfficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab-paclitaxel.
International journal of cancerWork-related exposure to asbestos and criminal liability: Forensic challenges from a nine-year autopsy experience.
Legal medicine (Tokyo, Japan)Clinical Importance of Molecular Biomarkers in Pleural Mesothelioma.
CancersImmune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: Efficacy, Real-World Outcomes, and the Search for Predictive Biomarkers.
Current oncology (Toronto, Ont.)Prognostic effect of systemic inflammation in patients undergoing cytoreductive surgery and hyperthermic intrathoracic chemotherapy.
Turk gogus kalp damar cerrahisi dergisiFive-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.
Journal of clinical oncology : official journal of the American Society of Clinical OncologyPleural Fluid Cytology-Histology Correlation in Patients With Malignant Pleural Mesothelioma: A Series of 26 Cases.
Cytopathology : official journal of the British Society for Clinical Cytology[The 9th TNM classification of thoracic tumors].
Annales de pathologieMoving Beyond Morphology: Toward a Morpho-Molecular Classification of Pleural Mesothelioma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung CancerJejunal Metastasis from Malignant Pleural Mesothelioma during Long-Term Nivolumab Therapy: A Case Report and Literature Review.
Surgical case reportsFDG and FAPI PET-based response evaluation to reduced-dose nivolumab in pleural mesothelioma: A case report.
Clinical physiology and functional imagingA proteomics approach to identify predictive blood biomarkers for pleural mesothelioma in prospective cohorts.
Clinical and experimental medicineHigh KAP1 expression promotes pleural mesothelioma cell proliferation and metastasis.
The International journal of biological markersMalignant Pleural Mesothelioma in an Asbestos Industry Worker: A Posthumous Case Report from Haryana, India.
Indian journal of occupational and environmental medicinePresent and future of cytoreductive surgery and hyperthermic intrathoracic chemotherapy for pleural metastases: a narrative review.
European respiratory review : an official journal of the European Respiratory SocietyPleural Mesothelioma: Current Therapeutic Strategies and Future Directions.
Current oncology reportsOptimising response to immunotherapies in pleural mesothelioma: clinical data and alternative models for the evaluation of new strategies.
ThoraxCandidate biomarkers to identify mesothelioma patients at risk of developing venous thromboembolism post-surgery.
Scientific reportsImmunotherapy advances in pleural mesothelioma.
Therapeutic advances in medical oncologyBeyond Asbestos: Malignant Pleural Mesothelioma Revealing Lynch Syndrome Through Mismatch Repair Deficiency.
CureusPrognostic Value of Systemic Inflammation and Clinical Variables in Malignant Pleural Mesothelioma: A Real-World Study.
Archivos de bronconeumologiaThe Role of Dosimetric Parameters in Radiation Pneumonitis: A Functional Approach in Adjuvant Treatment of Malignant Pleural Mesothelioma.
CancersRadiofrequency Ablation for Recurrent Pleural Mesothelioma.
CancersThe MARS2 Trial - Is Surgical Treatment of Pleural Mesothelioma a Relic of the Past?
Annali italiani di chirurgiaSATB2 Induces Malignant Transformation and Cancer Stem Cell Characteristics, and Inhibition of Its Expression Reverses Drug Resistance in Mesothelioma.
CellsValidation of chemoresistance phenotypes in pleural mesothelioma across 2D, 3D, and in vivo models.
Scientific reportsBAP-1 in the diagnosis of malignant pleural mesothelioma.
Respiratory medicine and researchFeasibility of multimodality treatment, including pleurectomy decortication, in carefully selected patients with sarcomatoid mesothelioma.
Translational lung cancer researchCommentary on Notification and Recordkeeping of Occupational Mesothelioma in India.
American journal of industrial medicineDisseminated tuberculosis secondary to polymicrobial co-infection following long-term immunotherapy for sarcomatoid mesothelioma: A case report.
Respiratory medicine case reports[Pleural mesothelioma due to asbestos exposure in operating room].
Epidemiologia e prevenzioneDisaster on MARS2? Lessons Learned from Modern Day Outcomes of Surgery for Pleural Mesothelioma.
The Annals of thoracic surgeryProjecting future mortality risk of pleural mesothelioma in Italy (2020-2034): Bayesian age-period-cohort analysis over 40 years of death registration.
Frontiers in public health[Clinical effect analysis of sintilimab combined with chemotherapy in the treatment of malignant pleural mesothelioma].
Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseasesEvaluation of respiratory toxicity and peritoneal mesothelioma induced by heat-treated and milled amosite following intratracheal and intraperitoneal injection in rats.
Industrial healthMechanisms of Chemoresistance in Malignant Pleural Mesothelioma: The Regulatory Role of miRNAs.
Archives of medical researchPembrolizumab Plus Platinum Doublet Chemotherapy With Lenvatinib in Unresectable Pleural Mesothelioma as First-Line Treatment (PENINSULA): A Study Protocol for a Single-Arm, Multi-Institutional, Phase II Clinical Trial.
Clinical lung cancerTreatment Patterns, Clinical Outcomes, Health Care Resource Use, and Costs in Older Adults with Malignant Pleural Mesothelioma in the United States, 2007-2020.
Advances in therapyPD-L1 and BAP1 as Prognostic Biomarkers in Malignant Pleural Mesothelioma.
CellsReactive Oxygen Species Drive Cell Migration and PD-L1 Expression via YB-1 Phosphorylation in Pleural Mesothelioma.
Antioxidants (Basel, Switzerland)The Diagnostic Trap in Radiation-Induced Mesothelioma: Kinetic-Morphological Decoupling Masks Molecular Aggression.
CancersEvaluation of an educational program for nurses on the care coordination of pleural mesothelioma patients: A pilot randomized controlled trial.
Japan journal of nursing science : JJNSAn Autopsy Case of Pleural Mesothelioma Progressed Rapidly With Multiple Organ Metastases During Immune Checkpoint Inhibitor Therapy.
Pathology internationalSpatio-temporal trends in pleural mesothelioma mortality in Italy: a 40-year analysis by calendar period and birth cohort.
International journal of epidemiologyPrognostic value and clinical significance of tumoral PD-L1 and stromal α-SMA expression in diffuse pleural mesothelioma.
NeoplasmaIntrathoracic 90 Y-NZ-16 therapy improves efficacy and reduces toxicity in pleural mesothelioma mice.
Nuclear medicine communicationsCancer-Specific Antihuman Podoplanin Antibody chLpMab-2f Exerts Antitumor Effects Against Pleural Mesothelioma.
Cancer scienceNintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG).
Lung cancer (Amsterdam, Netherlands)Mesothelioma Contrast Pharmacokinetics: A Feasibility Trial of the Use of Pharmacokinetic Analysis in Small-Volume Pleural Malignancy.
Radiology. Cardiothoracic imaging[Histiocytosis X discovered after chemotherapy treatment for mesothelioma].
Revue medicale de LiegeHematogenous dissemination of malignant pleural mesothelioma: An autopsy case of gallbladder metastasis causing obstructive jaundice.
Respiratory medicine case reportsArtificial Intelligence in Pleural Diseases: Current Applications and Next Steps.
Thoracic research and practiceHypoxia induces alterations in the volatile signature of pleural mesothelioma cells.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapieGlobal bibliometric analysis of pleural mesothelioma biomarkers (2002-2024): trends and emerging frontiers.
Journal of thoracic diseaseThe Accuracy of Video-Assisted Thoracic Surgery Pleural Biopsy in Patients with Suspected Diffuse Pleural Mesothelioma: A Real-Life Study.
Journal of clinical medicineMulti-omic screening for pleural mesothelioma in Asbestos-Exposed Populations: A literature review and Recommendations.
Lung cancer (Amsterdam, Netherlands)Real-world outcomes of first-line immunotherapy and subsequent systemic therapies in pleural mesothelioma: a multicenter study in China.
Translational lung cancer researchPrognostic Value of Fibroblast Activation Protein-Directed PET Imaging in Pleural Mesothelioma.
Journal of nuclear medicine : official publication, Society of Nuclear MedicineTargeting key proteins of pleural mesothelioma using plumbagin-indole-3-propionic acid ester: Insights from network pharmacology, molecular dynamics simulation and machine learning-based analysis.
Computational biology and chemistryJournal of Thoracic Oncology 20th Anniversary Series Surgery.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung CancerA Rare Case of Akathisia After Removal of Subdural Hematoma During Treatment for Malignant Pleural Mesothelioma: Akathisia Induced by Brain Injury or Immune Checkpoint Inhibition.
Case reports in oncological medicineIntegrating polygenic and methylation risk scores for pleural mesothelioma risk stratification.
International journal of cancerInfluence of Subcellular Localization on the Cytotoxicity of Targeted α-Therapy.
Journal of nuclear medicine : official publication, Society of Nuclear MedicineDeterminants of Response to Immune Checkpoint Blockade in Pleural Mesothelioma: Molecular, Immunological, and Clinical Perspectives.
CancersDemographic disparities in temporal trends and geographic variations of malignant pleural and peritoneal mesothelioma incidence in Pennsylvania, 1990-2019.
Cancer causes & control : CCCThe Role of Radiotherapy After Pleurectomy/Decortication for Malignant Pleural Mesothelioma: State of the Art.
Journal of personalized medicineLocoregional therapies in advanced and recurrent pleural mesothelioma: A systematic review.
Lung cancer (Amsterdam, Netherlands)Impact of hyperthermic intrathoracic chemotherapy during cytoreductive surgery with diaphragmatic resection.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyFibroblast-like cells in mesothelioma can derive from tumor cells.
Cell death and differentiation[Occupational cancer in Poland - epidemiological analysis and challenges based on data from the Central Register of Occupational Diseases].
Medycyna pracyTrends in Pleural Mesothelioma Incidence and Survival in Metropolitan and Nonmetropolitan Areas in the United States.
Cancer medicineMalignant mesothelioma in rare sites: two case reports.
Frontiers in oncologyRucaparib in refractory pleural mesothelioma harboring somatic pathogenic BRCA1 and BRCA2 mutation. A report of two cases.
Lung cancer managementDevelopment of a history-taking form for mesothelioma patients at risk of exposure to asbestos.
Public health actionPleural Mesothelioma Diagnosis for the Pulmonologist: Steps Along the Way.
CancersCirculating Biomarkers and Targeted Therapy in Pleural Mesothelioma.
CancersThe usefulness of full-thickness biopsy during semi-rigid pleuroscopy for differentiating between malignant pleural mesothelioma and non-specific pleurisy.
BMC pulmonary medicineEarly severe immune-related pneumonitis, hepatitis, and agranulocytosis with radiographic response in sarcomatoid malignant pleural mesothelioma treated with nivolumab and ipilimumab: a case report highlighting dual liver biopsies and rechallenge decision-making.
Therapeutic advances in medical oncology[Diagnostics of lung diseases based on small specimens : Biopsies and cytology].
Pathologie (Heidelberg, Germany)Immunotherapy for pleural mesothelioma: from innovation to the frontlines of core clinical questions.
Discover oncologyStaging pleural mesothelioma revitalized.
The British journal of radiologyDecoding the role of mesothelin in tumor dynamics and targeted treatment innovations.
Molecular biomedicineHuman lysine oxidase-like 3 high expression as a potential biomarker and association with poor prognosis in pleural mesothelioma.
The International journal of biological markersA Descriptive Summary of Tumor-Associated MUC1 (TA-MUC1) Expression in Epithelial Malignancies: A Systematic Review of Case Reports and Case Series.
CureusMultiomic, Histologic, and scRNA-seq Profiling of Pleural Mesothelioma Reveals Negative Prognosis Associated With a Novel Uncommitted Molecular Phenotype.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung CancerPembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study.
The Lancet. OncologyCirculating microRNAs as biomarkers for risk assessment and prognostic stratification of pleural mesothelioma.
Lung cancer (Amsterdam, Netherlands)Bis-Oxadiazole Assemblies as NO-Releasing Anticancer Agents.
PharmaceuticsLoss of Argininosuccinate Synthetase-1 (ASS1) Occurs in Esophageal Adenocarcinoma and Represents a Promising Biomarker for Therapy with Pegargiminase.
CancersProteomics of malignant pleural mesothelioma under hypoxic and normoxic conditions in a large animal (porcine) tumor model.
BMC cancerIgG4-related pleurisy with suspected asbestos involvement.
BMJ case reportsFirst-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors.
ESMO openHyperthermic Intrathoracic Chemotherapy and Photodynamic Therapy: A Single-Institution Experience for Malignant Pleural Diseases.
OncologyPositron emission tomography/computed tomography in risk-factor-negative young female with malignant pleural mesothelioma: A case report and review of literature.
World journal of clinical casesComprehensive analysis reveals prognostic gene set that could impacts the response to chemotherapy and immunotherapy outcomes in malignant pleural mesothelioma.
Clinical and experimental medicineCase Report: IL-6 suppression: a potential strategy for mitigating severe immune-related adverse events in nivolumab and ipilimumab therapy for malignant pleural mesothelioma.
Frontiers in oncologyCurrent approaches, barriers, and future directions in pleural mesothelioma diagnostics: results from an Italian National Survey.
PathologicaMethylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies.
Molecular oncologyNeoadjuvant systemic therapy for pleural mesothelioma patients: a systematic review.
Translational lung cancer researchEZH2 Inhibition in Mesothelioma Cells Increases the Release of Extracellular Vesicles That Skew Neutrophils Toward a Protumor Phenotype.
International journal of molecular sciencesAtypical abdominal pain: uncovering malignant peritoneal mesothelioma in suspected Crohn's disease: a case report.
Journal of gastrointestinal oncologyHealthy Mexicans exposed to erionite: a preliminary study of early-damage biomarkers for malignant pleural mesothelioma.
Environmental geochemistry and healthDistant Metastatic Pattern and Its Prognostic Significance in Malignant Pleural Mesothelioma: A Population-Based Study Based on a Machine Learning Model.
The clinical respiratory journalComparison of Cytoplasmic and Nuclear MTAP Loss in Pleural Effusion Cytology: Correlation With Homozygous p16/CDKN2A Deletion.
Cytopathology : official journal of the British Society for Clinical CytologyAdvances in diagnosis and management of pleural mesothelioma: the Danish clinical guidelines.
European clinical respiratory journalIntratumour, anatomical and temporal heterogeneity in mesothelioma.
ThoraxMalignant pleural mesothelioma classification and survival prediction with CT imaging using ResNet.
European radiologyRisk factors, prognostic factors, and nomograms for distant metastasis in patients with malignant pleural mesothelioma: A population-based retrospective study.
The Journal of international medical researchPleural Mesothelioma: Ninth Edition of the TNM Staging Classification.
Radiology. Cardiothoracic imagingUse of patient-derived organoids for pleural mesothelioma 3-D modeling.
American journal of physiology. Lung cellular and molecular physiologyCombination of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer - a brief update.
Frontiers in immunologySalvage resection after immunotherapy for giant undifferentiated pleomorphic sarcoma of the chest wall.
Journal of surgical case reportsNarciclasine as a Novel Treatment for Lung Cancer and Malignant Pleural Mesothelioma: Insights from 3D Tumor Spheroid Models.
International journal of molecular sciencesDual HDAC and PI3K Inhibitor CUDC-907 Inhibits Growth of Pleural Mesothelioma: The Impact of Cisplatin Sensitivity and Myc Expression.
CellsStaging of Pleural Mesothelioma with the Ninth Edition TNM System: Problems Solved and Some That Remain.
RadiologyDevelopment of a Mesothelin-Binding Engineered Scaffold Protein as a Theranostic for Pleural Mesothelioma.
Bioconjugate chemistryPD-L1 expression as a prognostic factor for postoperative outcomes in pleural mesothelioma.
Translational lung cancer researchCephalomannine as in vitro and in vivo anticancer agent in mesothelioma cells: mechanisms of action.
BMC cancerLong-term survival of nonoccupational pleural mesothelioma: a case report and review of the literature.
Journal of medical case reportsFL496, an FL118-derived small molecule, induces growth inhibition, senescence, and apoptosis of malignant pleural mesothelioma (MPM) cells, and exhibits anti-MPM tumor efficacy strikingly superior to the pemetrexed-cisplatin combination.
Journal of experimental & clinical cancer research : CRResveratrol Affects Cell Activities, Induces Apoptosis and Regulates AMPK Signaling Pathway in Pleural Mesothelioma Cells.
FASEB journal : official publication of the Federation of American Societies for Experimental BiologyMolecular Characterization of Pericardial Mesothelioma With Constrictive and Recurrent Pericarditis: TAZ Amplification and Hippo Pathway.
JACC. Case reportsA tumor-on-a-chip for in vitro study of CAR-T cell immunotherapy in solid tumors.
Nature biotechnologyA Rare Clinical Presentation of Malignant Pleural Mesothelioma With Central Nervous System Metastases: A Case Report.
CureusApical Malignant Pleural Mesothelioma Presenting as Horner's Syndrome: A Case Report.
CureusChest Wall Reconstruction Using a Titanium Mesh Plate and an Expanded Polytetrafluoroethylene Sheet: A Case Report.
Surgical case reportsPeri-procedural cardiac arrest at medical thoracoscopy in a patient with pleural mesothelioma causing resultant heart failure and an intractable pleural effusion.
Breathe (Sheffield, England)Perioperative Treatments in Pleural Mesothelioma: State of the Art and Future Directions.
CancersThe Role of Breath Analysis in the Non-Invasive Early Diagnosis of Malignant Pleural Mesothelioma (MPM) and the Management of At-Risk Individuals.
Molecules (Basel, Switzerland)Peritoneal Mesothelioma in a Patient with Long-Standing Crohn's Disease: Cause or Coincidence?
GE Portuguese journal of gastroenterology[Cutaneous metastasis of pleural mesothelioma].
Dermatologie (Heidelberg, Germany)Discovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesothelioma.
Lung cancer (Amsterdam, Netherlands)Tumor Treating Fields: An Innovative Therapy for Glioblastoma and Other Solid Tumors.
Journal of the advanced practitioner in oncologyEpidemiology and clinical characteristics of mesothelioma in the Chinese population: a multicenter study.
Therapeutic advances in medical oncologyThe role of non-coding RNAs in pleural mesothelioma.
Translational oncologyManganese-doped nanotheranostic system for MRI-guided photothermal therapy of malignant pleural mesothelioma: in vivo study.
Frontiers in chemistryComparison of imaging based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed paraffin-embedded tumor samples.
Nature communicationsExternal validation of pathological T adjustments in the ninth edition of the pleural mesothelioma tumor-node-metastasis classification.
Frontiers in oncologyChallenges in Identifying and Diagnosing Asbestos-Related Diseases in Emerging Economies: A Global Health Perspective.
Annals of global healthPharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma.
Cancer researchCan the positive findings from POD1UM-304 improve patient care worldwide?
The Lancet. Respiratory medicinePleural fluid biomarkers for the diagnosis and management of malignant pleural effusions: a clinical review.
Critical reviews in clinical laboratory sciencesRadiotherapy-Induced Pleural Mesothelioma in a Childhood Leukaemia Survivor: A Case Report.
Respirology case reportsTwo Cases of Diffuse Pleural Mesothelioma Discovered After Spontaneous Pneumothorax.
Pathology internationalEfficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in the treatment of diffuse pleural mesothelioma: a systematic review and meta-analysis.
Frontiers in immunologyRadiologist's Guide to the Ninth Edition TNM Staging System for Quantitative and Qualitative Assessment of Pleural Mesothelioma.
RadiologyThe Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets.
OncoTargets and therapyInclusion of anti-vascular therapy as a promising option for later-line treatment of malignant pleural mesothelioma: a retrospective study.
Journal of thoracic diseasePleurectomy/Decortication Versus Extrapleural Pneumonectomy in Pleural Mesothelioma: A Systematic Review and Meta-Analysis of Survival, Mortality, and Surgical Trends.
Journal of clinical medicineOligometastatic Mesothelioma Treated with Ablative Radiotherapy (OMAR): A Multicenter Study.
CancersMalignant Local Seeding in Procedure Tracts of Pleural Mesothelioma: Incidence and Novel Risk Factors in 308 Patients.
CancersPerioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses.
Nature medicineCytoreductive surgery with radical pleurectomy/Decortication and intraoperative photodynamic therapy as a treatment for stage IVa and pleural recurrence thymic tumors.
Photodiagnosis and photodynamic therapyMiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial.
Translational oncologyAnti-AK5 limbic encephalitis in a patient with pleural mesothelioma.
Journal of neurologyInhibition of YB-1 phosphorylation enhances cisplatin activity and disrupts cell division in pleural mesothelioma.
British journal of cancerPleural Mesothelioma: Pathogenesis, Diagnosis, Treatment, Prognosis, and Survival.
MedCommMultiomics Insights into the Mechanism and Enhanced Efficacy of Tumor Treating Fields (TTFields) Therapy in Glioblastoma.
Journal of proteome researchCDKN2A deletion is associated with immune desertification in diffuse pleural mesothelioma.
Journal of experimental & clinical cancer research : CRReactivation of Latent Varicella-Zoster Virus Leading to Meningitis in a Patient With Malignant Pleural Mesothelioma Undergoing Immune Checkpoint Inhibitor Therapy: A Case Report.
CureusIdentification of Cembrane Diterpenoids from Sinularia sp. That Reduce the Viability of Diffuse Pleural Mesothelioma Cell Lines.
Journal of natural productsPartial Response to Nivolumab and Ipilimumab in a Patient With Malignant Pleural Mesothelioma and Pre-Existing Myasthenia Gravis Without Severe Flares or Immune-Related Adverse Events: A Case Report.
Respirology case reportsPrognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy.
ImmunotherapyA rare presentation of peritoneal mesothelioma: Esophageal encasement and Sister Mary Joseph nodule.
Radiology case reportsPemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab.
Lung cancer (Amsterdam, Netherlands)Evaluating the diagnostic utility of [⁶⁸Ga]Ga-Pentixafor in solid tumors: a systematic review.
Annals of nuclear medicineGelatinous pleural effusion in advanced lung adenocarcinoma: a case report.
Journal of medical case reportsA Promising Prognostic Indicator for Pleural Mesothelioma: Pan-Immuno-Inflammation Value.
Journal of clinical medicinePleural mesothelioma patients and ex-exposed asbestos workers are immunologically poor responders to oncogenic Merkel cell polyomavirus.
Translational lung cancer researchInhibition of LDHB triggers DNA damage and increases cisplatin sensitivity in pleural mesothelioma.
OncogenesisInsights into the molecular mechanisms underlying the function of lysyl oxidase like 1 in cancers.
PeerJSingle-cell RNA-sequencing as a potential approach for studying intratumor heterogeneity in pleural mesothelioma.
Lung cancer (Amsterdam, Netherlands)First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study.
Lung cancer (Amsterdam, Netherlands)Pipeline to evaluate YAP-TEAD inhibitors indicates TEAD inhibition represses NF2-mutant mesothelioma.
Life science allianceAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Mesotelioma.
É de uma associação que acompanha esta doença? Fale com a gente →
Doença com base genética
Um médico geneticista pode ajudar no diagnóstico de Mesotelioma e no aconselhamento genético da família.
Doenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Perguntas frequentes
O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu
A principal causa associada ao desenvolvimento deste câncer é o histórico de exposição ao amianto. Alterações em genes como BAP1, WT1 e BCL10 também estão associadas ao comportamento molecular da neoplasia.
Referências
Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete
10 publicações do grafo RarasNet (PubMed) · 7 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Citar este verbete
Raras. (s.d.). Mesotelioma. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/mesotelioma
Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
Mesotelioma
📋 Origem dos dados
Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.
- Doença rara (ontologia)
- fonte: Orphanet
- Identificador unificado
- fonte: MONDO
- Genética mendeliana
- fonte: OMIM
- Codificação WHO/SUS
- fonte: WHO ICD-10 / DATASUS
- CID-11 (futuro)
- fonte: WHO ICD-11
- NIH/GARD
- fonte: GARD (NIH)
- Indexação biomédica
- fonte: MeSH (NLM)
- Dado público estruturado
- fonte: Wikidata
- Medicamentos aprovados FDA
- fonte: FDA OpenFDA
- Reposicionamento
- fonte: Drug Repurposing Hub
- Ensaios clínicos
- fonte: ClinicalTrials.gov
